Naringin prevents the structural alterations produced in the small intestine by experimental type 1 Diabetes Mellitus

TALAMONI G; RIVOIRA M; COLLIN A; MUKDSI J; RODRÍGUEZ V

Córdoba

Jornada; XXIII Jornada de Investigación Científica; 2022

FCM-UNC

Diabetic enteropathy is one of the common complications of type 1 Diabetes mellitus (DM1). Naringin (NAR) is a flavonoid with antioxidant, anti-inflammatory and immunomodulatory effects in various tissues. Our objective was to evaluate if NAR prevents the alterations produced in the duodenum, jejunum and ileum by DM1 at the histological and ultrastructural level. Two-month-old male Wistar rats were divided into four groups (n=6 for each group): 1) controls, 2) diabetics: rats treated with 60 mg streptozotocin/kg b.w., 3) diabetics treated with NAR40 (40 mg/kg b.w.) 4) diabetics treated with NAR80 (80 mg/kg b.w.). After 30 days treatment, the rats were sacrificed, and the small intestine was removed and weighed. Histological sections of the duodenum, jejunum, and ileum were measured for villus height and width (Image J ProPlus). Ultrastructure was analyzed by transmission electron microscopy. ANOVA/Bonferroni was used for statistical analysis. The results revealed that diabetic rats had a longer small intestine compared to controls. Treatment with both doses of NAR prevented this increase (Controls:112.27±3.02; STZ:142.71±8.43*; STZ+NAR40:119.13±4.11; STZ+NAR80:116, 85±4.09 cm; *p